Please wait while the formulary information is being retrieved.
Drug overview for PLENVU (peg 3350/sodium sulfate/sod chloride/kcl/ascorbate sod/vit c):
Generic name: peg 3350/sodium sulfate/sod chloride/KCl/ascorbate sod/vit C (PEG/ih-LECK-troh-lite)
Drug class: Hypertonic Laxatives
Therapeutic class: Gastrointestinal Therapy Agents
Glycerin (glycerol), polyethylene glycol (PEG), and sorbitol are hyperosmotic laxatives.
No enhanced Uses information available for this drug.
Generic name: peg 3350/sodium sulfate/sod chloride/KCl/ascorbate sod/vit C (PEG/ih-LECK-troh-lite)
Drug class: Hypertonic Laxatives
Therapeutic class: Gastrointestinal Therapy Agents
Glycerin (glycerol), polyethylene glycol (PEG), and sorbitol are hyperosmotic laxatives.
No enhanced Uses information available for this drug.
DRUG IMAGES
PLENVU POWDER PACKETS
The following indications for PLENVU (peg 3350/sodium sulfate/sod chloride/kcl/ascorbate sod/vit c) have been approved by the FDA:
Indications:
Bowel evacuation
Professional Synonyms:
None.
Indications:
Bowel evacuation
Professional Synonyms:
None.
The following dosing information is available for PLENVU (peg 3350/sodium sulfate/sod chloride/kcl/ascorbate sod/vit c):
Prior to bowel cleansing, a copy of the patient information (containing careful instructions on the proper methods of reconstitution and administration of the laxatives) provided by the manufacturer should be given to the patient.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| PLENVU POWDER PACKETS | Maintenance | Adults take by oral route as directed per package instructions |
No generic dosing information available.
The following drug interaction information is available for PLENVU (peg 3350/sodium sulfate/sod chloride/kcl/ascorbate sod/vit c):
There are 0 contraindications.
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Bortezomib/Ascorbic Acid (Vitamin C) SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Vitamin C can form a complex with the boronic acid moiety of the bortezomib molecule, preventing its absorption into cells.(1-4) This may protect normal tissue in the body, which may have higher levels of Vitamin C.(5) CLINICAL EFFECTS: Concurrent administration of Vitamin C may result in decreased bortezomib activity.(1-4) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Instruct patients receiving bortezomib therapy not to begin taking vitamin C supplements without consulting their oncologist first. Patients who are instructed to take vitamin C should follow their oncologist's instructions on how to separate dosages and should be carefully monitored for bortezomib efficacy. DISCUSSION: An in vitro study with human plasma and multiple myeloma cells found that high levels of vitamin C (following 1 gram/day of ascorbic acid for 4 days) decreased bortezomib effectiveness by 26%. An in vivo study in mice found that vitamin C administration with bortezomib completely blocked the response of bortezomib.(6) An in vitro study in rat Schwann cells and myeloma cells(4) and an in vivo study in mice(7) found that delayed administration of vitamin C had no effect on bortezomib effects. In an in vivo study in multiple myeloma patients, concurrent ascorbic acid, arsenic trioxide, bortezomib, and high-dose melphalan in which ascorbic acid was administered close to bortezomib, the combination was safe and well tolerated, but produced no changes in response rates.(8) In another in vivo study in multiple myeloma patients, a regimen of ascorbic acid, bortezomib, and melphalan in which bortezomib was administered in the morning and ascorbic acid in the evening was found to be safe and efficacious, with 74% of patients responding to therapy.(9) |
BORTEZOMIB, BORUZU, VELCADE |
| Tenapanor/Laxatives; Stool Softeners SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Tenapanor commonly causes diarrhea of mild to moderate severity. Laxatives and stool softeners may increase the incidence or severity of diarrhea.(1) CLINICAL EFFECTS: Concurrent use of laxatives or stool softeners with tenapanor may increase the risk of severe diarrhea.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of tenapanor states that patients should be instructed to avoid stool softeners and laxatives with tenapanor. If severe diarrhea occurs, tenapanor should be discontinued.(1) DISCUSSION: In clinical trials, 43-53% of CKD patients on dialysis treated with tenapanor developed diarrhea. Diarrhea usually occurred soon after treatment initiation and was severe in 5% of patients.(1) |
XPHOZAH |
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Deferoxamine/Ascorbic Acid (Vitamin C) SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: It is believed that ascorbic acid increases the iron available for chelation from an labile intracellular iron pool. Ascorbic acid may then facilitate iron-induced oxidative tissue damage.(1) CLINICAL EFFECTS: Dietary ascorbic acid may increase the absorption of dietary iron. Supplemental ascorbic acid therapy given during chelation therapy may improve iron output;(1-9) however, excessive dosages may result in cardiac toxicity from iron-induced oxidative tissue damage.(1,2,11-13) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Ascorbic acid intake is often restricted in patients with iron overload; however, it has been used in conjunction with deferoxamine to increase iron excretion.(2) Supplemental ascorbic acid therapy should only be initiated after one month of deferoxamine therapy. Ascorbic acid therapy should only be given in patients receiving deferoxamine regularly and the dose should be given after the infusion has started. The dosage of ascorbic acid should be limited to 50 mg daily in children under 10 years of age; 100 mg daily in older children; and 200 mg daily, in divided doses, in adults.(2) Cardiac function should be monitored in patients receiving concurrent therapy. Discontinue ascorbic acid therapy in patients who develop cardiac dysfunction.(2) DISCUSSION: Supplemental ascorbic acid therapy given during chelation therapy has been shown to improve iron output,(1-9) possibly by increasing iron available for chelation from an labile intracellular iron pool.(1) However, dosages in excess of 500 mg daily have been associated with cardiac dysfunction.(1,2,11-13) |
DEFEROXAMINE MESYLATE, DESFERAL MESYLATE |
The following contraindication information is available for PLENVU (peg 3350/sodium sulfate/sod chloride/kcl/ascorbate sod/vit c):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 8 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Familial hyperkalemic periodic paralysis |
| Gastrointestinal obstruction |
| Gastrointestinal perforation |
| Hemolytic anemia from pyruvate kinase and g6PD deficiencies |
| Hyperkalemia |
| Ileus |
| Toxic colitis |
| Toxic megacolon |
There are 19 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Anuria |
| Calcium oxalate renal calculi |
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
| Complete atrioventricular block |
| Dehydration |
| Gastric retention |
| Gastrointestinal ulcer |
| Glucose-6-phosphate dehydrogenase (g6Pd) deficiency |
| Hyperchloremia |
| Hyperoxaluria |
| Hypokalemia |
| Hyponatremia |
| Hyporeninemic hypoaldosteronism |
| Myotonia congenita - autosomal dominant form |
| Predisposition to aspiration |
| Seizure disorder |
| Severe burns |
| Severe heart block |
There are 7 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Hemochromatosis |
| Hypocalcemia |
| Kidney disease with likely reduction in glomerular filtration rate (GFr) |
| Kidney disease with reduction in glomerular filtration rate (GFr) |
| Severe ulcerative colitis |
| Severe vomiting |
| Sickle cell disease |
The following adverse reaction information is available for PLENVU (peg 3350/sodium sulfate/sod chloride/kcl/ascorbate sod/vit c):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 37 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Acidosis Hypercalcemia Hyperkalemia Hypernatremia Hyperuricemia Hypocalcemia Hypokalemia Hypomagnesemia Hyponatremia Hypophosphatemia Urticaria |
| Rare/Very Rare |
|---|
|
Abnormal hepatic function tests Acute pulmonary edema Anaphylaxis Angioedema Asystole Atrial fibrillation Cardiac arrhythmia Dyspnea Esophageal perforation Facial edema Gastritis Hypertension Ischemic colitis Kidney disease with reduction in glomerular filtration rate (GFr) Lip swelling Peripheral edema Pulmonary edema Seizure disorder Skin rash Syncope Tachycardia Throat constriction Tongue swelling Tremor Ulceration of colon Upper GI bleed |
There are 22 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Abdominal distension Abdominal pain with cramps Acute abdominal pain Dehydration Malaise Nausea Polydipsia Rectal irritation Sleep disorder Upper abdominal pain Vomiting |
Dizziness Dyspepsia Headache disorder Rhinorrhea |
| Rare/Very Rare |
|---|
|
Chest tightness Chills Fever Fluid volume disorder Palpitations Pruritus of skin Skin inflammation |
The following precautions are available for PLENVU (peg 3350/sodium sulfate/sod chloride/kcl/ascorbate sod/vit c):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for PLENVU (peg 3350/sodium sulfate/sod chloride/kcl/ascorbate sod/vit c):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for PLENVU (peg 3350/sodium sulfate/sod chloride/kcl/ascorbate sod/vit c)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool